Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial

Citation
Cooper ME, Rosenstock J, Kadowaki T, et al. Diabetes Obes Metab 2020;22:1062–73.